

Amgen Inc.  
Law Department  
51 University Street  
Seattle, WA 98101

Telephone: 206-265-4071  
Facsimile: 206-233-0644  
e-mail: Sprunges@amgen.com

**FAX MESSAGE - PLEASE DELIVER IMMEDIATELY**

Send to: **Examiner William Moore**  
**Art Unit 1652**  
U.S. Patent and Trademark Office

FAX: (703) 746-3169

From: Suzanne A. Sprunger

Date: 30 October 2003

No. of pages including this page: 8

**Re: Application Ser. No. 09/634,252**

AS WE DISCUSSED ON TUESDAY 28 OCTOBER.

THANK YOU!

— SA8

If transmission problems occur contact Suzanne Sprunger at 206-265-4071.

Form II → case is allowable

Wash,  
this is Applicant's  
FAX following your  
suggestion in Tuesday's  
interview.  
Claims 34 → 36 are  
now canceled and a new  
claim 50 appears  
— B.M.

**CONFIDENTIALITY NOTICE:** This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Application No. 09/634,252  
DRAFT Amendment After Final dated 30 Oct 2003

2862-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No: 09/634,252  
Applicants: Douglas P. CERRETTI  
Filing Date August 7, 2000  
Title: METALLOPROTEASE-DISINTEGRIN ADAM23 (SVPH3-17)  
NUCLEIC ACIDS  
Docket No.: 2862-US  
Examiner: William MOORE  
Art Unit: 1652

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DRAFT AMENDMENT AND RESPONSE AFTER FINAL REJECTION**

Responsive to the Final Office Action mailed May 29, 2003 ("the Office Action"), Applicants respectfully request the Examiner enter the following amendments in the above identified application:

**Listing of Claims** begins on page 2 of this paper.

**Remarks** begin on page 6 of this paper.